



**July 29, 2020**

The Manager- Listing  
BSE Limited  
(BSE: 507685)

The Manager- Listing  
National Stock Exchange of India Limited,  
(NSE: WIPRO)

The Market Operations,  
NYSE: New York  
(NYSE: WIT)

Dear Sir/Madam,

**Sub: Press Release**

Please find attached herewith copy of the Press Release which is being released today.

**For Wipro Limited**

A handwritten signature in black ink, appearing to read "G Kothandaraman", is positioned below the "For Wipro Limited" text.

**G Kothandaraman  
General Manager- Finance**

Registered Office:

Wipro Limited  
Doddakannelli  
Sarjapur Road  
Bengaluru 560 035  
India

T : +91 (80) 2844 0011  
F : +91 (80) 2844 0256  
E : info@wipro.com  
W : wipro.com  
C : L32102KA1945PLC020800





## **Wipro named a Worldwide Leader in Drug Safety Services by IDC MarketScape**

**East Brunswick, New Jersey, USA and Bangalore, India – July 29, 2020:** Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been named a leader in *IDC MarketScape: Worldwide Life Science Drug Safety Services, 2019–2020 Vendor Assessment — Building for Innovation* ([Doc # US45863116](#), January 2020).

The report mentions that “Relative to other vendors discussed in this document and based on feedback from multiple customer references, [Wipro](#) received high marks for its solid delivery capabilities, rapid onboarding, ability to deliver high value for money, and significant commitment to investing in innovation in the Drug Safety Services (DSS) space.”

“The Life Sciences industry is in transition. Technological advances and scientific discoveries contribute to new capabilities, data, and insights, that have the potential to transform existing best practices and accelerate the development of new treatments and cures,” said **Lynne Dunbrack, Group Vice President, IDC Health Insights.**

She added, “As an experienced global service provider to the life science industry, Wipro is well positioned for continued growth. Transforming from a service partner to strategic partner is a mature transition, and Wipro is benefiting its existing clients, while building up a project-based innovation success portfolio across the life sciences value chain.”

Highlighting Wipro’s capabilities, the report mentions “Wipro's approach to DSS Centre of Excellence is multifaceted, with groups focused on optimizing DSS client engagement, [Pharmacovigilance \(PV\) process transformation](#) leveraging cognitive automation, and PV quality and process excellence. This approach is very well aligned with industry and sponsor needs, and Wipro is already beginning to gain success in its innovation and transformation initiatives.”

Pharmaceutical and Biotech companies are increasingly turning to digital transformation for help. In light of this, Wipro’s rich R&D domain experts worldwide and strategic partners have delivered innovative thinking and reinvented processes for 8 out of 10 pharmaceuticals. Partnering with global software solutions providers, supported by its own enabled start-up ecosystem, Wipro continues to leverage its end-to-end integration and digital consulting expertise to accelerate and cover the full range of R&D solutions required. This is supported by industry solutions like [Digital R&D Labs](#) that create collaborative environments to accelerate drug discovery and drug discovery time, [AI enabled literature search](#) and [Pharmacovigilance services](#) leveraging Wipro HOLMES™, [AI Digital Imaging](#), [Digital Integrated Clinical Enterprise](#), and [Digital anti-counterfeiting cold chain](#) to name a few.

“Global regulatory authorities, pharmaceutical firms and caregivers continue to push the frontiers of drug safety through sustained efforts. Our drug safety philosophy is characterized by sound understanding of clinical and regulatory legislation supported by comprehensive technological expertise – built on a mature global footprint.” said **Steve Duryee, Global Head**

**of Life Sciences, Wipro Limited.** “We aim to forge a long-term and trusting relationship with our clients who give us this great opportunity to enable drug safety successes worldwide.”

Download the report excerpt [here](#).

### **About IDC MarketScape**

IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.

### **About Wipro Limited**

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading global information technology, consulting and business process services company. We harness the power of cognitive computing, hyper-automation, robotics, cloud, analytics and emerging technologies to help our clients adapt to the digital world and make them successful. A company recognized globally for its comprehensive portfolio of services, strong commitment to sustainability and good corporate citizenship, we have over 180,000 dedicated employees serving clients across six continents. Together, we discover ideas and connect the dots to build a better and a bold new future.

### **Media Contact:**

Nisha Chandrasekaran

Wipro Limited

[nisha.chandrasekaran@wipro.com](mailto:nisha.chandrasekaran@wipro.com)

### **Forward-Looking Statements**

The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry. The conditions caused by the COVID-19 pandemic could decrease technology spending, adversely affect demand for our products, affect the rate of customer spending and could adversely affect our customers’ ability or willingness to purchase our offerings, delay prospective customers’ purchasing decisions, adversely impact our ability to provide on-site consulting services and our inability to deliver our customers or delay the provisioning of our offerings, all of which could adversely affect our future sales, operating results and overall financial performance. Our operations may also be negatively affected by a range of external factors related to the COVID-19 pandemic that are not within our control. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange

Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at [www.sec.gov](http://www.sec.gov). We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.